Frontiers in Pharmacology | Pharmacogenetics and Pharmacogenomics

Review

Published on 21 Dec 2022

Triplex-forming oligonucleotides as an anti-gene technique for cancer therapy

in Pharmacogenetics and Pharmacogenomics

Chun Li
Zunzhen Zhou
Chao Ren
Yi Deng
Feng Peng
Qiongfen Wang
Hong Zhang
Yuan Jiang

Frontiers in Pharmacology

doi 10.3389/fphar.2022.1007723

7,251 views
23 citations

Original Research

Published on 13 Dec 2022

Identification and drug metabolic characterization of four new CYP2C9 variants CYP2C972-75 in the Chinese Han population

in Pharmacogenetics and Pharmacogenomics

Fang-Ling Zhao
Qing Zhang
Shuang-Hu Wang
Yun Hong
Shan Zhou
Quan Zhou
Pei-Wu Geng
Qing-Feng Luo
Jie-Fu Yang
Hao Chen

Frontiers in Pharmacology

doi 10.3389/fphar.2022.1007268

3,879 views
5 citations

Review

Published on 05 Dec 2022

Targeting cancer-related inflammation with non-steroidal anti-inflammatory drugs: Perspectives in pharmacogenomics

in Pharmacogenetics and Pharmacogenomics

Hongjin Lai
Yi Liu
Juan Wu
Jie Cai
Hui Jie
Yuyang Xu
Senyi Deng

Frontiers in Pharmacology

doi 10.3389/fphar.2022.1078766

6,523 views
16 citations

Clinical Trial

Published on 05 Dec 2022

Effects of CYP3A4*22 and CYP3A5 on clinical outcome in patients treated with ticagrelor for ST-segment elevation myocardial infarction: POPular Genetics sub-study

in Pharmacogenetics and Pharmacogenomics

Jaouad Azzahhafi
Thomas O. Bergmeijer
Wout W. A. van den Broek
Dean R. P. P. Chan Pin Yin
Senna Rayhi
Joyce Peper
Willem L. Bor
Daniel M. F. Claassens
Ron H. N. van Schaik
Jurriën M. ten Berg

Frontiers in Pharmacology

doi 10.3389/fphar.2022.1032995

2,307 views
2 citations

Original Research

Published on 25 Nov 2022

Associations of HLA-A and HLA-B with vancomycin-induced drug reaction with eosinophilia and systemic symptoms in the Han-Chinese population

in Pharmacogenetics and Pharmacogenomics

Chuang-Wei Wang
Wei-Chen Lin
Wei-Ti Chen
Chun-Bing Chen
Chun-Wei Lu
Hsin-Han Hou
Rosaline Chung-Yee Hui
Jennifer Wu
Chih-Jung Chang
Ya-Ching Chang

Frontiers in Pharmacology

doi 10.3389/fphar.2022.954596

3,771 views
9 citations

Original Research

Published on 24 Nov 2022

Eight pharmacokinetic genetic variants are not associated with the risk of bleeding from direct oral anticoagulants in non-valvular atrial fibrillation patients

in Pharmacogenetics and Pharmacogenomics

Alessandra M. Campos-Staffico
Michael P. Dorsch
Geoffrey D. Barnes
Hao-Jie Zhu
Nita A. Limdi
Jasmine A. Luzum

Frontiers in Pharmacology

doi 10.3389/fphar.2022.1007113

4,278 views
12 citations

Original Research

Published on 21 Nov 2022

Genotyping for HLA risk alleles versus patch tests to diagnose anti-seizure medication induced cutaneous adverse drug reactions

in Pharmacogenetics and Pharmacogenomics

Lisanne E. N. Manson
Patricia C. Y. Chan
Stefan Böhringer
Henk-Jan Guchelaar

Frontiers in Pharmacology

doi 10.3389/fphar.2022.1061419

3,058 views
3 citations

Original Research

Published on 17 Nov 2022

Identification of SNPs associated with methotrexate treatment outcomes in patients with early rheumatoid arthritis

in Pharmacogenetics and Pharmacogenomics

Shrikant S. Kolan
Gaoyang Li
Franco Grimolizzi
Joe Sexton
Guro Goll
Tore K. Kvien
Nina Paulshus Sundlisæter
Manuela Zucknick
Siri Lillegraven
Espen A. Haavardsholm

Frontiers in Pharmacology

doi 10.3389/fphar.2022.1075603

3,922 views
4 citations

Mini Review

Published on 15 Nov 2022

Global perspectives on CYP2D6 associations with primaquine metabolism and Plasmodium vivax radical cure

in Pharmacogenetics and Pharmacogenomics

Jasmine M. Olvany
Scott M. Williams
Peter A. Zimmerman

Frontiers in Pharmacology

doi 10.3389/fphar.2022.752314

2,638 views
2 citations

Editorial

Published on 11 Nov 2022

Editorial: Translation and implementation of pharmacogenomic testing in daily clinical practice: Considering current challenges and future needs

in Pharmacogenetics and Pharmacogenomics

Wojciech Miltyk
George P. Patrinos
Celine Verstuyft
Marieke Coenen
Alireza Tafazoli

Frontiers in Pharmacology

doi 10.3389/fphar.2022.1053027

1,811 views
1 citation

Editorial

Published on 11 Nov 2022

Editorial: Pharmacogenomics in neglected populations

in Pharmacogenetics and Pharmacogenomics

Mariana R. Botton
Jorge Duconge
Fernanda Rodrigues-Soares

Frontiers in Pharmacology

doi 10.3389/fphar.2022.1081117

1,872 views
2 citations

Editorial

Published on 10 Nov 2022

Editorial: How pharmacogenomics, epigenetics, and data analysis could improve anticancer treatment?

in Pharmacogenetics and Pharmacogenomics

Abdeslam Jaafari
Subramani Srinivasan
Mounir Tilaoui

Frontiers in Pharmacology

doi 10.3389/fphar.2022.1067022

1,895 views

Original Research

Published on 09 Nov 2022

SLC7A8 coding for LAT2 is associated with early disease progression in osteosarcoma and transports doxorubicin

in Pharmacogenetics and Pharmacogenomics

Evelien G. E. Hurkmans
Jan B. Koenderink
Jeroen J. M. W. van den Heuvel
Yvonne M. H. Versleijen-Jonkers
Melissa H. S. Hillebrandt-Roeffen
Johanne M. Groothuismink
Hanneke I. Vos
Winette T. A. van der Graaf
Uta Flucke
Grigor Muradjan

Frontiers in Pharmacology

doi 10.3389/fphar.2022.1042989

3,507 views
3 citations

Review

Published on 04 Nov 2022

Relationship between miRNA and ferroptosis in tumors

in Pharmacogenetics and Pharmacogenomics

Shang-Ming Dai
Feng-Jiao Li
Hui-Zhi Long
Zi-Wei Zhou
Hong-Yu Luo
Shuo-Guo Xu
Li-Chen Gao

Frontiers in Pharmacology

doi 10.3389/fphar.2022.977062

5,736 views
37 citations

Original Research

Published on 28 Oct 2022

Acetyl coenzyme A kinetic studies on N-acetylation of environmental carcinogens by human N-acetyltransferase 1 and its NAT1*14B variant

in Pharmacogenetics and Pharmacogenomics

Mariam R. Habil
Mark A. Doll
David W. Hein

Frontiers in Pharmacology

doi 10.3389/fphar.2022.931323

2,017 views
2 citations

Original Research

Published on 26 Oct 2022

The association of ARRB1 polymorphisms with response to antidepressant treatment in depressed patients

in Pharmacogenetics and Pharmacogenomics

Kenneth Chappell
Abd El Kader Ait Tayeb
Romain Colle
Jérôme Bouligand
Khalil El-Asmar
Florence Gressier
Séverine Trabado
Denis Joseph David
Bruno Feve
Laurent Becquemont

Frontiers in Pharmacology

doi 10.3389/fphar.2022.974570

2,192 views
7 citations

Triplex-forming oligonucleotides as an anti-gene technique for cancer therapy

Identification and drug metabolic characterization of four new CYP2C9 variants CYP2C9*72-*75 in the Chinese Han population

Targeting cancer-related inflammation with non-steroidal anti-inflammatory drugs: Perspectives in pharmacogenomics

Effects of CYP3A4*22 and CYP3A5 on clinical outcome in patients treated with ticagrelor for ST-segment elevation myocardial infarction: POPular Genetics sub-study

Associations of HLA-A and HLA-B with vancomycin-induced drug reaction with eosinophilia and systemic symptoms in the Han-Chinese population

Eight pharmacokinetic genetic variants are not associated with the risk of bleeding from direct oral anticoagulants in non-valvular atrial fibrillation patients

Genotyping for HLA risk alleles versus patch tests to diagnose anti-seizure medication induced cutaneous adverse drug reactions

Identification of SNPs associated with methotrexate treatment outcomes in patients with early rheumatoid arthritis

Global perspectives on CYP2D6 associations with primaquine metabolism and Plasmodium vivax radical cure

Editorial: Translation and implementation of pharmacogenomic testing in daily clinical practice: Considering current challenges and future needs

Editorial: Pharmacogenomics in neglected populations

Editorial: How pharmacogenomics, epigenetics, and data analysis could improve anticancer treatment?

SLC7A8 coding for LAT2 is associated with early disease progression in osteosarcoma and transports doxorubicin

Relationship between miRNA and ferroptosis in tumors

Acetyl coenzyme A kinetic studies on N-acetylation of environmental carcinogens by human N-acetyltransferase 1 and its NAT1*14B variant

The association of ARRB1 polymorphisms with response to antidepressant treatment in depressed patients

Identification and drug metabolic characterization of four new CYP2C9 variants CYP2C972-75 in the Chinese Han population